ArticleClinical nuclear medicine2026
Comparison of PSMA/FAPI Bispecific Tracer ¹⁸F-ALF-NOTA-PSFA-1 and ¹⁸F-FDG PET/CT in the Detection of Primary Clear Cell Sarcoma of Bone.
Article in Clinical nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 43-year-old man presented with left hip pain. Contrast-enhanced CT demonstrated lytic destruction of the left ilium and sacrum with associated soft-tissue extension, suggestive of a bone tumor. Subsequent ¹⁸F-FDG PET/CT revealed only mild or no FDG avidity in lesions involving the ilium, sacrum, and right fibula. In contrast, these lesions demonstrated intense or elevated uptake on PSMA/FAPI bispecific tracer ¹⁸F-ALF-NOTA-PSFA-1 PET/CT. These observations indicate that ¹⁸F-ALF-NOTA-PSFA-1 PET/CT holds considerable potential for sarcoma detection and may support the development of PSMA/FAPI bispecific targeted receptor radionuclide therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.